Management von entzündlich rheumatischen Erkrankungen während und nach Malignomen

Mercer LK, Davies R, Galloway JB, Low A, Lunt M, Dixon WG, Watson KD, Symmons DPM, Hyrich KL (2013) Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. Baillieres Clin Rheumatol 52:9198 Nocturne G, Mariette X (2015) Sjögren syndrome-associated lymphomas: an update on pathogenesis and management. Br J Haematol 168(3):317–327 Feldman CH, Liu J, Feldman S, Solomon DH, Kim SC (2017) Risk of high-grade cervical dysplasia and cervical cancer in women with systemic lupus erythematosus receiving immunosuppressive drugs. Lupus 26(7):682–689 Lopez-Olivo MA, Colmegna I, Karpes Matusevich AR, Qi SR, Zamora NV, Sharma R, Pratt G, Suarez-Almazor ME (2020) Systematic review of recommendations on the use of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and cancer. Arthritis Care Res (Hoboken) 72(3):309–318 Singh JA, Furst DE, Bharat A et al (2012) 2012 update of the 2008 American college of rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 64(5):625–639 Singh JA, Saag KG, Bridges SL Jr et al (2016) 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 68(1):1–25 Penn I (1997) Evaluation of transplant candidates with pre-existing malignancies. Ann Transplant 2(4):14–17 Tarella C, Passera R, Magni M et al (2011) Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma. J Clin Oncol 29(7):814–824 Fraenkel L, Bathon JM, England BR, St Clair EW et al (2021) 2021 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 73(7):924–939 Vanni KMM, Berliner N, Paynter NP, Glynn RJ, MacFadyen J, Colls J, Lu F, Xu C, Ridker PM, Solomon DH (2020) Adverse effects of low-dose methotrexate in a randomized double-blind placebo-controlled trial: adjudicated hematologic and skin cancer outcomes in the cardiovascular inflammation reduction trial. ACR Open Rheumatol 2(12):697–704 Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, Germino R, Menon S, Sun Y, Wang C, Shapiro AB, Kanik KS, Connell CA (2022) Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritisc. N Engl J Med 386(4):316–326 Strangfeld A, Hierse F, Rau R et al (2010) Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 12:R5 Dixon WG, Watson KD, Lunt M et al (2010) Influence of antitumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British society for rheumatology biologics register. Arthritis Care Res 62:755–763 Pappas DA, Rebello S, Liu M, Schenfeld J, Li Y, Collier DH, Accortt NA (2019) Therapy with biologic agents after diagnosis of solid malignancies: results from the Corrona registry. J Rheumatol 46(11):1438–1444 Dreyer L, Cordtz RL, Hansen IMJ, Kristensen LE, Hetland ML, Mellemkjaer L (2018) Risk of second malignant neoplasm and mortality in patients with rheumatoid arthritis treated with biological DMARDs: a Danish population-based cohort study. Ann Rheum Dis 77(4):510–514 Raaschou P, Soederling J, Turesson C, Askling J (2018) Tumor necrosis factor inhibitors and cancer recurrence in Swedish patients with rheumatoid arthritis: a nationwide population-based cohort study. Ann Intern Med 169:291–299 Xie W, Xiao S, Huang Y, Sun X, Gao D, Ji L, Li G, Zhang Z (2020) A meta-analysis of biologic therapies on risk of new or recurrent cancer in patients with rheumatoid arthritis and a prior malignancy. Rheumatology (Oxford) 59(5):930–939 Shelton E, Laharie D, Scott FI et al (2016) Cancer recurrence following immune-suppressive therapies in patients with immune-mediated diseases: a systematic review and meta-analysis. Gastroenterology 151(1):97–109.e4 Mamtani R, Clark AS, Scott FI et al (2016) Association between breast cancer recurrence and immunosuppression in rheumatoid arthritis and inflammatory bowel disease: a cohort study. Arthritis Rheumatol 68:2403–2411 Schmalzing M, Strangfeld A, Tony HP (2016) Medikamentöse Therapie der rheumatoiden Arthritis bei Malignomanamnese. Epidemiologische Daten. Z Rheumatol 75:22–31 Regierer AC, Strangfeld A (2018) Rheumatoid arthritis treatment in patients with a history of cancer. Curr Opin Rheumatol 30:288–294 De Cock D, Hyrich K (2018) Malignancy and rheumatoid arthritis: epidemiology, risk factors and management. Best Pract Res Clin Rheumatol 32:869–886 Lange E, Blizzard L, Venn A, Francis H, Jones G (2016) Disease-modifying anti-rheumatic drugs and non-melanoma skin cancer in inflammatory arthritis patients: a retrospective cohort study. Rheumatology (Oxford) 55(9):1594–1600 Rizzi R, Curci P, Delia M, Rinaldi E, Chiefa A, Specchia G, Liso V (2009) Spontaneous remission of „methotrexate-associated lymphoproliferative disorders“ after discontinuation of immunosuppressive treatment for autoimmune disease. Review of the literature. Med Oncol 26(1):1–9 Hellgren K, Baecklund E, Backlin C et al (2017) Rheumatoid arthritis and risk of malignant lymphoma: is the risk still increased? Arthritis Rheumatol 69(4):700–708 Behrens F, Koehm M, Burkhardt H (2011) Update 2011: leflunomide in rheumatoid arthritis—strengths and weaknesses. Curr Opin Rheumatol 23(3):282–287 Ruiz-Irastorza G, Ugarte A, Egurbide MV, Garmendia M, Pijoan JI, Martinez-Berriotxoa A, Aguirre C (2007) Antimalarials may influence the risk of malignancy in systemic lupus erythematosus. Ann Rheum Dis 66(6):815–817 Fardet L, Nazareth I, Petersen I (2017) Effects of chronic exposure of hydroxychloroquine/chloroquine on the risk of cancer, metastasis, and death: a population-based cohort study on patients with connective tissue diseases. Clin Epidemiol 9:545–554 Lopez A, Pouillon L, Beaugerie L, Danese S, Peyrin-Biroulet L (2018) Colorectal cancer prevention in patients with ulcerative colitis. Best Pract Res Clin Gastroenterol 32–33:103–109 Moore TJ Safety perspectives: cancer risks of biological products for psoriasis. https://www.ismp.org/quarterwatch/safety-perspectives. Zugegriffen: 29. März 2018 Thai A, Prindiville T (2010) Hepatosplenic T‑cell lymphoma and inflammatory bowel disease. J Crohns Colitis 4:511–522 Ertz-Archambault N, Kosiorek H, Taylor GE et al (2017) Association of therapy for autoimmune disease with myelodysplastic syndromes and acute myeloid leukemia. JAMA Oncol 3(7):936–943 Scott FI, Mamtani R, Brensinger CM et al (2016) Risk of nonmelanoma skin cancer associated with the use of immunosuppressant and biologic agents in patients with a history of autoimmune disease and nonmelanoma skin cancer. JAMA Dermatol 152(2):164–172 Muellenhoff MW, Koo JY (2012) Cyclosporine and skin cancer: an international dermatologic perspective over 25 years of experience. A comprehensive review and pursuit to define safe use of cyclosporine in dermatology. J Dermatolog Treat 23(4):290–304 Vos M, Plasmeijer EI, van Bemmel BC et al (2018) Azathioprine to mycophenolate mofetil transition and risk of squamous cell carcinoma after lung transplantation. J Heart Lung Transplant 37(7):853–859 Hellbacher E, Hjorton K, Backlin C et al (2019) Malignant lymphoma in granulomatosis with polyangiitis: subtypes, clinical characteristics and prognosis. Acta Oncol 58(11):1655–1659 Kang KY, Kim HO, Yoon HS et al (2010) Incidence of cancer among female patients with systemic lupus erythematosus in Korea. Clin Rheumatol 29(4):381–388 Raaschou P, Simard JF, Asker Hagelberg C, Askling J (2016) Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden. BMJ 352:i262 Mercer LK, Askling J, Raaschou P, Dixon WG, Dreyer L, Hetland ML, Strangfeld A, Zink A, Mariette X, Finckh A, Canhao H, Iannone F, Zavada J, Morel J, Gottenberg JE, Hyrich KL, Listing J (2017) Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers. Ann Rheum Dis 76(2):386–391 Staples MP, March L, Hill C, Lassere M, Buchbinder R (2019) Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: an update from the Australian rheumatology association database (ARAD) prospective cohort study. BMC Rheumatol 3:1 Cordtz R, Mellemkjær L, Glintborg B, Hetland ML, Dreyer L (2015) Malignant progression of precancerous lesions of the uterine cervix following biological DMARD therapy in patients with arthritis. Ann Rheum Dis 74(7):1479–1480 Calip GS, Patel PR, Adimadhyam S, Xing S, Wu Z, Sweiss K, Schumock GT, Lee TA, Chiu BC (2018) Tumor necrosis factor-alpha inhibitors and risk of non-Hodgkin lymphoma in a cohort of adults with rheumatologic conditions. Int J Cancer 143(5):1062–1071 Mercer LK, Galloway JB, Lunt M et al (2017) Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British society for rheumatology biologics register for rheumatoid arthritis. Ann Rheum Dis 76(3):497–503 Perez-Ruiz E, Minute L, Otano I et al (2019) Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA‑4 and PD‑1 immunotherapy. Nature 569(7756):428–432 Bertrand F, Montfort A, Marcheteau E et al (2017) TNFα blockade overcomes resistance to anti-PD‑1 in experimental melanoma. Nat Commun 8(1):2256 Badran YR, Cohen JV, Brastianos PK, Parikh AR, Hong TS, Dougan M (2019) Concurrent therapy with immune checkpoint inhibitors and TNFα blockade in patients with gastrointestinal immune-related adverse events. J Immunother Cancer 7(1):226 Kim ST, Tayar J, Trinh VA, Suarez-Almazor M, Garcia S, Hwu P, Johnson DH, Uemura M, Diab A (2017) Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series. Ann Rheum Dis 76(12):2061–2064 Kim SC, Pawar A, Desai RJ, Solomon DH, Gale S, Bao M, Sarsour K, Schneeweiss S (2019) Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: a multi-database cohort study. Semin Arthritis Rheum 49(2):222–228 Wadström H, Frisell T, Askling J (2017) Anti-rheumatic therapy in Sweden (ARTIS) study group. Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, Tocilizumab, Abatacept, or Rituximab in clinical practice: a nationwide cohort study from Sweden. JAMA Intern Med 177(11):1605–1612 Solomon DH, Kremer JM, Fisher M, Curtis JR, Furer V, Harrold LR, Hochberg MC, Reed G, Tsao P, Greenberg JD (2014) Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs. Semin Arthritis Rheum 43(4):489–497 Montastruc F, Renoux C, Dell’Aniello S, Simon TA, Azoulay L, Hudson M, Suissa S (2019) Abatacept initiation in rheumatoid arthritis and the risk of cancer: a population-based comparative cohort study. Rheumatology (Oxford) 58(4):683–691 Redeker I, Herzer P, Kühne C, Schwarze I, Schaefer M, Strangfeld A (2021) Occurrence of basal cell and squamous cell carcinomas of the skin under different DMARD therapies [abstract]. Arthritis Rheumatol 73(suppl 10). https://acrabstracts.org/abstract/occurrence-of-basal-cell-and-squamous-cell-carcinomas-of-the-skin-under-different-dmard-therapies/. Zugegriffen: 30.06.2022 de Germay S, Bagheri H, Despas F, Rousseau V, Montastruc F (2020) Abatacept in rheumatoid arthritis and the risk of cancer: a world observational post-marketing study. Rheumatology (Oxford) 59(9):2360–2367 Nast A, Amelunxen L, Augustin M et al (2017) S3-Leitlinie zur Therapie der Psoriasis vulgaris (AWMF-Register Nr. 013/001) Fiorentino D, Ho V, Lebwohl MG, Leite L, Hopkins L, Galindo C, Goyal K, Langholff W, Fakharzadeh S, Srivastava B, Langley RG (2017) Risk of malignancy with systemic psoriasis treatment in the psoriasis longitudinal assessment registry. J Am Acad Dermatol 77(5):845–854.e5 Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ (2017) Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet 390(10105):1833–1842 Porpaczy E, Tripolt S, Hoelbl-Kovacic A et al (2018) Aggressive B‑cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. Blood 132(7):694–706 Pemmaraju N, Kantarjian H, Nastoupil L, Dupuis M, Zhou L, Pierce S, Patel KP, Masarova L, Cortes J, Verstovsek S (2019) Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy. Blood 133(21):2348–2351 Cohen SB, van Vollenhoven RF, Winthrop KL, Zerbini CAF, Tanaka Y, Bessette L, Zhang Y, Khan N, Hendrickson B, Enejosa JV, Burmester GR (2021) Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis 80(3):304–311 Smolen JS, Genovese MC, Takeuchi T, Hyslop DL, Macias WL, Rooney T, Chen L, Dickson CL, Riddle Camp J, Cardillo TE, Ishii T, Winthrop KL (2019) Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment. J Rheumatol 46(1):7–18 Kremer JM, Bingham CO 3rd, Cappelli LC, Greenberg JD, Madsen AM, Geier J, Rivas JL, Onofrei AM, Barr CJ, Pappas DA, Litman HJ, Dandreo KJ, Shapiro AB, Connell CA, Kavanaugh A (2021) Postapproval comparative safety study of tofacitinib and biological disease-modifying antirheumatic drugs: 5‑year results from a United States-based rheumatoid arthritis registry. ACR Open Rheumatol 3(3):173–184